To determine whether TXNIP synergizes with imatinib in producing growth inhibition for CML treatment, we introduced the drug JQ1 (TXNIP activator) and SBI477 (TXNIP inhibitor). Here, TXNIP is linked to chronic myelogenous leukemia, BCR-ABL1 positive.